First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab or bevacizumab in patients with RAS/BRAF wild-type (WT) metastatic colorectal carcinoma (mCRC)

被引：1
|
作者：
Rivera, F. [1 ]
Karthaus, M. [2 ]
Hecht, J. R. [3 ]
Fasola, G. [4 ]
Canon, J. -L. [5 ]
Koukakis, R. [6 ]
Demonty, G. [7 ]
Schwartzberg, L. [8 ]
机构：
[1] Hosp Univ Marques de Valdecilla, Santander, Spain
[2] Klinikum Neuperlach, Stadt Klinikum Munchen, Munich, Germany
[3] Univ Calif Los Angeles, David Geffen Sch Med, Santa Monica, CA USA
[4] Univ Hosp Santa Maria della Misericordia, Udine, Italy
[5] Grand Hop Charleroi, Charleroi, Belgium
[6] Amgen Ltd, Uxbridge, Middx, England
[7] Amgen Europe GmbH, Zug, Switzerland
[8] West Clin, Memphis, TN USA
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
10.1093/annonc/mdv234.13
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD-014
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Tumor response outcomes in first-line treatment of wild-type (WT) RAS metastatic colorectal carcinoma (mCRC) following modified FOLFOX6 (mFOLFOX6) + either panitumumab (pmab) or bevacizumab (bev).
    Rivera, Fernando
    Karthaus, Meinolf
    Hecht, J. Randolph
    Fasola, Gianpiero
    Canon, Jean-Luc
    Koukakis, Reija
    Terwey, Jan-Henrik
    Schwartzberg, Lee Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab (pmab) or bevacizumab (bev) in wild-type (WT) RAS metastatic colorectal carcinoma (mCRC): Tumor response outcomes beyond RECIST.
    Rivera, Fernando
    Karthaus, Meinolf
    Hecht, J. Randolph
    Fasola, Gianpiero
    Canon, Jean-Luc Re
    Koukakis, Reija
    Terwey, Jan-Henrik
    Schwartzberg, Lee Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [3] Efficacy of first-line modified FOLFOX6 with panitumumab or bevacizumab in RAS wild-type/BRAF wild-type metastatic colorectal cancer: impact of tumour symptoms and extent of disease
    Rivera, F.
    Peeters, M.
    Douillard, J-Y.
    Taieb, J.
    Koukakis, R.
    Demonty, G.
    Siena, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [4] COST-EFFECTIVENESS ANALYSIS OF PANITUMUMAB PLUS MFOLFOX6 VERSUS BEVACIZUMAB PLUS MFOLFOX6 FOR FIRST-LINE TREATMENT OF PATIENTS WITH WILD-TYPE RAS METASTATIC COLORECTAL CANCER
    Graham, C. N.
    Hechmati, G.
    Hjelmgren, J.
    De Liege, F.
    Lanier, J.
    Knoof, A.
    Knox, H.
    Barber, B.
    de Pouvourville, G.
    VALUE IN HEALTH, 2014, 17 (07) : A632 - A632
  • [5] Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer
    Graham, Christopher N.
    Hechmati, Guy
    Hjelmgren, Jonas
    de Liege, Frederique
    Lanier, Julie
    Knox, Hediyyih
    Barber, Beth
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (16) : 2791 - 2801
  • [6] First-line panitumumab versus bevacizumab in combination with mFOLFOX6 for RAS wild-type metastatic colorectal cancer: PARADIGM trial results
    Muro, K.
    Watanabe, J.
    Shitara, K.
    Yamazaki, K.
    Ohori, H.
    Shiozawa, M.
    Yasui, H.
    Oki, E.
    Sato, T.
    Naitoh, T.
    Komatsu, Y.
    Kato, T.
    Hihara, M.
    Soeda, J.
    Yamamoto, K.
    Akagi, K.
    Ochiai, A.
    Uetake, H.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S377 - S377
  • [7] Safety and efficacy of AMG 655 plus modified FOLFOX6 (mFOLFOX6) and bevacizumab (B) for the first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC)
    Saltz, L.
    Infante, J.
    Schwartzberg, L.
    Stephenson, J.
    Rocha-Lima, C.
    Galimi, F.
    Dillingham, K.
    Hsu, M.
    Wiezorek, J.
    Fuchs, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] Phase I trial of erlotinib (E), modified FOLFOX6 (mFOLFOX6), and bevacizumab (B) as first-line therapy for metastatic colorectal cancer (MCRC)
    Singh, D.
    Rath, L.
    Bokar, J. A.
    Brell, J. M.
    Cooney, M. M.
    Dowlati, A.
    Gibbons, J.
    Nock, C. J.
    Savvides, P.
    Krishnamurthi, S. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.
    Yoshino, Takayuki
    Watanabe, Jun
    Shitara, Kohei
    Yasui, Hirofumi
    Ohori, Hisatsugu
    Shiozawa, Manabu
    Yamazaki, Kentaro
    Oki, Eiji
    Sato, Takeo
    Naitoh, Takeshi
    Komatsu, Yoshito
    Kato, Takeshi
    Hihara, Masamitsu
    Soeda, Junpei
    Yamamoto, Kouji
    Akagi, Kiwamu
    Ochiai, Atsushi
    Uetake, Hiroyuki
    Tsuchihara, Katsuya
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
  • [10] Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer
    Rivera, Fernando
    Valladares, Manuel
    Gea, Salvador
    Lopez-Martinez, Noemi
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (06) : 574 - 584
12345